FDA panel debates risks of antidepressants during pregnancy amid expert concerns
TL;DR Summary
An FDA panel's discussion on antidepressants during pregnancy was criticized by psychiatrists for spreading misinformation and lacking balance, with some panelists emphasizing unproven risks and questioning drug efficacy, despite medical consensus supporting the safety and importance of SSRIs for pregnant women with depression.
- FDA panel promotes misinformation about antidepressants during pregnancy, psychiatrists say NBC News
- F.D.A. Panel Debates ‘Black Box’ Warning for Antidepressants in Pregnancy The New York Times
- The FDA’s new SSRI experts have long questioned antidepressant use Endpoints News
- Certain antidepressants used during pregnancy may cause lifelong mental health issues in children, sugges Times of India
- FDA to consider warning against antidepressants Caledonian Record
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
5 min
vs 6 min read
Condensed
96%
1,092 → 43 words
Want the full story? Read the original article
Read on NBC News